1 December 2015 - In a further dossier assessment, the IQWiG has examined the benefit of pertuzumab in its second therapeutic indication, i.e. in pre-operative use. In this so-called neoadjuvant treatment, pertuzumab is used in HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence, also in combination with trastuzumab and chemotherapy. The study data presented resulted in a hint that pertuzumab is of lesser benefit than the appropriate comparator therapy.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/neoadjuvant-use-of-pertuzumab-in-her2-positive-breast-cancer-hint-of-lesser-benefit.7078.html